Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostacyclin for pulmonary hypertension.

N S Paramothayan1, T J Lasserson, A U Wells

  • 1Division of Physiological Medicine, St George's Hospital Medical School, Cranmer Terrace, London, UK, SW17 0RE.

The Cochrane Database of Systematic Reviews
|July 26, 2002
PubMed
Summary

Intravenous prostacyclin therapy significantly improves exercise capacity and cardiopulmonary hemodynamics in patients with primary pulmonary hypertension. While it may improve survival, further research is needed to confirm this effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease burden, comorbidities and antecedents of chronic cough phenotypes in Australian adults.

Pulmonology·2023
Same author

Preclinical interstitial lung disease in relatives of familial pulmonary fibrosis patients.

Pulmonology·2022
Same author

Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis.

European radiology·2017
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2016
Same author

Mould-sensitized adults have lower Th2 cytokines and a higher prevalence of asthma than those sensitized to other aeroallergens.

Allergy·2016
Same author

Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.

Arthritis & rheumatology (Hoboken, N.J.)·2015

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Primary pulmonary hypertension (PPH) is a severe condition leading to right ventricular failure with a poor prognosis.
  • Pulmonary hypertension, whether idiopathic or associated with conditions like scleroderma, shares clinical and hemodynamic similarities.
  • Prostacyclin and its stable analogue, Iloprost, are potent vasodilators with potential therapeutic applications.

Purpose of the Study:

  • To evaluate the effectiveness of prostacyclin or its analogues in treating idiopathic primary pulmonary hypertension.
  • To synthesize evidence from randomized controlled trials on prostacyclin's impact on PPH.

Main Methods:

  • A systematic search of the Cochrane Controlled Clinical Trials Register was conducted.
  • Four randomized controlled trials (RCTs) involving patients with primary pulmonary hypertension were selected and reviewed.

Related Experiment Videos

  • Study quality was assessed, data extracted independently, and outcomes analyzed using statistical methods.

    • Main Results:

    • Intravenous epoprostenol improved exercise capacity (SMD 0.69) and hemodynamic variables, including a reduction in mean pulmonary artery pressure (WMD -6.3 mmHg).
    • A trend towards improved mortality was observed with epoprostenol (Peto OR 0.32), though not statistically significant in all analyses.
    • Adverse events, primarily related to indwelling catheters, were common.

    Conclusions:

    • Short-term (12-week) intravenous prostacyclin administration enhances exercise capacity, NYHA functional class, and cardiopulmonary hemodynamics in PPH patients.
    • Prostacyclin therapy shows potential for improving mortality in primary pulmonary hypertension.
    • Further investigation is warranted to fully elucidate the long-term benefits and risks.